Derleme
Yıl 2023,
Cilt: 3 Sayı: 3, 354 - 368, 30.09.2023
Öz
The doses of digital drugs bring different experiences than adult patients. Digoxin is a potentially dangerous drug due to the narrow safety margin of therapeutic, toxic and lethal doses. Many toxic responses are extensions of their therapeutic effects. Therefore, the nurse should maintain a high index of suspicion for signs of toxicity when administering digital drugs.
Digital toxicity is a condition that requires early intervention. While children in adolescence and school childhood can express this process in a way that they can express themselves, such a sharing is not possible in the newborn and infancy period. In this process, pediatric nurses should observe the early signs and symptoms of toxicity in the institutions they provide health care, take an appropriate approach and evaluate them. In this review article, the use of digital drugs used in chronic diseases and the responsibilities of the pediatric nurse will be shared in detail.
Anahtar Kelimeler
Kaynakça
- 1. Mohammed Ibrahim NA. An up-to-date review of digoxin toxicity and its management. Int J Clin Pharmacol. 2009;4(3):59-64. 2. Smith TW, Haber E. Digitalis (first of four parts). N Engl J Med. 1973;289(21):1125-29.
- 3. Brunton LL, Lazo JS, Parker LK. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw Hill; 2006. p.886-89, 921-23.
- 4. Roberts DM, Gallapatthy G, Dunuwille A, Chan BS. Pharmacological treatment of cardiac glycoside poisoning. Br J Clin Pharmacol. 2015;81(3):488–95.
- 5. Winter ME. Basic clinical pharmacokinetics. 4th ed. Baltimore: Lippincott Williams and Wilkins, 2004. p.183-21.
- 6. Packer M, Gheorghiade M, Young JB. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993; 329:1-7.
- 7. Newton GE, Tong JH, Schofield AM. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol. 1996;28(1):155–61.
- 8. Wong DL. Essentials of pediatric nursing. 10th ed. St. Louis: Mosby-Year Book; 2016. p.1472- 81.
- 9. Van Gelder IC, Hagens VE, Bosker HA. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40.
- 10. Khan IA, Nair CK, Singh N. Acute ventricular rate control in atrial fibrillation and atrial flutter. Int J Cardiol. 2004;(1):7-13.
- 11. Wyse DG, Waldo AL, DiMarco JP. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2009;347(23):1825-33.
- 12. Prybys KM. Deadly drug interactions in emergency medicine. Emerg Med Clin North Am. 2004;22(4):845-63.
- 13. Uretsky BF, Young JB, Shahidi FE. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the proved trial. J Am Coll Cardiol. 2012;22(4):955-62.
- 14. Pedersen KE. Digoxin interactions. J Intern Med. 1985;217(S697):24-5.
- 15. Aronow WS, Frishman WH, Cheng Lai A. Cardiovascular drug therapy in the elderly. Cardiol Rev. 2007;15(4):195-215.
- 16. Gruenwald J, Brendler T, Jaenicke C. PDR for herbal medicines. NJ: Medical Economics Company;1998. p.248-50.
- 17. Abebe W. An overview of herbal supplement utilization with particular emphasis on possible interactions with dental drugs and oral manifestations. J Dent Hyg 2003;77(1):37-46.
- 18. Demirezer Ö, Ersöz T, Saraçoğlu İ, Şener B. Tedavide kullanılan bitkiler “FFD Monografları” 1. Baskı. Ankara: MN Medikal ve Nobel Tıp Kitabevi: 2007. p.1-9, 129-37, 181- 94, 295-301.
- 19. Williamson E, Driver S, Baxter K. Stockley’s herbal medicines interactions 1st ed. Londra: Pharmaceutical Press; 2009. p.1-11, 24-6, 167-70, 195-6; 198-203, 207-18, 219-25, 272-6, 349- 52, 360-80, 394-97.
- 20. Smith TW. Digitalis: Mechanisms of action and clinical use. N Engl J Med. 1988;318(6):358-65.
- 21. Akyol A. Dijital zehirlenmesinde hemşirenin sorumlulukları. EGEHFD. 1999;15(2-3):151-63.
- 22. Bhatia SJ. Digitalis toxicity turning over a new leaf? West J Med. 1986;145(1)74-82.
- 23. Kanji S, MacLean RD. Cardiac glycoside toxicity: More than 200 years and counting. Crit Care Clin. 2012;28(4):527-35.
- 24. Park MK. The use of digoxin in infants and children with specific emphasis on dosage. J Pediatr 1986;108(6):871-7.
- 25. Das BB, Moskowitz WB, Butler J. Current and future drug and device therapies for pediatric heart failure patients: potential lessons from adult trials. Children (Basel). 2021;8(5):322.
- 26. Meissner JE. Reducing the risk of toxicity. Nursing 1980;10(9):32-37.
- 27. Soyka LF. Clinical pharmacology of digoksin. Pediatr Clin North Am. 1972;19(1):241-56.
- 28. Haklin H, Radomsky M, Blieden L, Frand M, Millman P, Boichis H. Steady state serum digoxin concentration in relation to digitalis toxicity in neonates and infants. Pediatrics. 1978;61(2):184-88.
- 29. Tuncok Y, Hazan E, Oto O, Guven H, Catalyurek H, Kalkan S. Relationship between high serum digoxin levels and toxicity. Int J Clin Pharmacol Ther. 1997;35(9):366-68.
- 30. Çiftçi E, Aydın S. Toxicological evaluation of digital glycosides in congestive heart failure. FABAD J Pharm Sci. 2018;43(3):296-307. 31. Goldberger AL, Goldberger ZD, Shvilkin A. Goldberger’s clinical electrocardiography. 8th ed. Elsevier; 2018. p.211-216.
- 32. Işık K. Acil Kalp hastalıklarında teşhis ve tedavi. 1. Basım. İstanbul Matbaası; İstanbul. 1986. p.251-63.
- 33. Cooke DM. Shielding Your Patient. Nursing 1992;22(7):44-47.
- 34. Murpy TG. Digoxin toxicity ventricular dysrhytmias to watch for. AJN. 1993;93(12):37-41.
- 35. Esen A. Dijital tedavisi ve hemşirenin sorumlulukları. EGEHFD. 1993;9:3.
- 36. Fee WH. Activated charcoal safe and effective for digoxin toxicity. Am J Med. 2008;116(6):430.
- 37. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila). 2012;49(10):910-41.
- 38. Kervancıoğlu M, Özbek MN, Devecioğlu C, Sucaklı İ. Ondört günlük bir yenidoğanda digoksin intoksikasyonu: Olgu sunumu. Dicle Univ Tip Fakul Derg, 2006;33(1):45-47.
- 39. Park MK, Salamat M. Park’s pediatric cardiology for practitioners, 4th edt. St.Louis, Missouri, Mosby; 2002. p.403-406.
- 40. Cambonie G, Haack K, Guyon G. Digitalis intoxication during the neonatal period: role of dehydration. Arch Pediatr. 2000;7(6):633-36.
- 41. Hu YH, Tai CT, Tsai CF, Huang MW. Improvement of adequate digoxin dosage: an application of machine learning approach. J Healthc Eng. 2018;3948245.
- 42. Yao SH, Tsai HT, Lin WL, Chen YC, Chou C, Lin HW. Predicting the serum digoxin concentrations of infants in the neonatal intensive care unit through an artificial neural network. BMC Pediatrics, 2019;19(1):517.
Yıl 2023,
Cilt: 3 Sayı: 3, 354 - 368, 30.09.2023
Öz
Dijital ilaçların kullanım dozları erişkin hastalardan daha farklı deneyimleri beraberinde getirmektedir. Digoksin, terapötik, toksik ve ölümcül dozların dar güvenlik sınırı nedeniyle potansiyel olarak tehlikeli bir ilaçtır. Birçok toksik tepki, terapötik etkilerinin uzantılarıdır. Bu nedenle, hemşire dijital ilaçları uygularken toksisite belirtileri için yüksek bir şüphe indeksi sürdürmelidir.
Dijital toksisite erken müdahaleyi beraberinde gerektirmesi gereken bir durumdur. Adölesan ve okul çocukluğu dönemindeki çocuklar bu süreci kendilerini ifade edebilecekleri şekilde dile getirebilirlerken, yenidoğan ve süt çocukluğu döneminde ise böyle bir paylaşım mümkün olamamaktadır. Bu süreçte pediatri hemşireleri sağlık bakımı verdikleri kurumlarda toksisite erken belirti ve bulgularını gözlemlemeli, uygun yaklaşımda bulunmalı ve değerlendirmeleri oldukça önemlidir. Bu derleme makalesinde özellikle kronik hastalıklarda kullanılan dijital ilaç kullanımı ve pediatri hemşiresinin sorumlulukları detaylı bir biçimde paylaşılacaktır.
Anahtar Kelimeler
Kaynakça
- 1. Mohammed Ibrahim NA. An up-to-date review of digoxin toxicity and its management. Int J Clin Pharmacol. 2009;4(3):59-64. 2. Smith TW, Haber E. Digitalis (first of four parts). N Engl J Med. 1973;289(21):1125-29.
- 3. Brunton LL, Lazo JS, Parker LK. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw Hill; 2006. p.886-89, 921-23.
- 4. Roberts DM, Gallapatthy G, Dunuwille A, Chan BS. Pharmacological treatment of cardiac glycoside poisoning. Br J Clin Pharmacol. 2015;81(3):488–95.
- 5. Winter ME. Basic clinical pharmacokinetics. 4th ed. Baltimore: Lippincott Williams and Wilkins, 2004. p.183-21.
- 6. Packer M, Gheorghiade M, Young JB. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993; 329:1-7.
- 7. Newton GE, Tong JH, Schofield AM. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol. 1996;28(1):155–61.
- 8. Wong DL. Essentials of pediatric nursing. 10th ed. St. Louis: Mosby-Year Book; 2016. p.1472- 81.
- 9. Van Gelder IC, Hagens VE, Bosker HA. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40.
- 10. Khan IA, Nair CK, Singh N. Acute ventricular rate control in atrial fibrillation and atrial flutter. Int J Cardiol. 2004;(1):7-13.
- 11. Wyse DG, Waldo AL, DiMarco JP. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2009;347(23):1825-33.
- 12. Prybys KM. Deadly drug interactions in emergency medicine. Emerg Med Clin North Am. 2004;22(4):845-63.
- 13. Uretsky BF, Young JB, Shahidi FE. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the proved trial. J Am Coll Cardiol. 2012;22(4):955-62.
- 14. Pedersen KE. Digoxin interactions. J Intern Med. 1985;217(S697):24-5.
- 15. Aronow WS, Frishman WH, Cheng Lai A. Cardiovascular drug therapy in the elderly. Cardiol Rev. 2007;15(4):195-215.
- 16. Gruenwald J, Brendler T, Jaenicke C. PDR for herbal medicines. NJ: Medical Economics Company;1998. p.248-50.
- 17. Abebe W. An overview of herbal supplement utilization with particular emphasis on possible interactions with dental drugs and oral manifestations. J Dent Hyg 2003;77(1):37-46.
- 18. Demirezer Ö, Ersöz T, Saraçoğlu İ, Şener B. Tedavide kullanılan bitkiler “FFD Monografları” 1. Baskı. Ankara: MN Medikal ve Nobel Tıp Kitabevi: 2007. p.1-9, 129-37, 181- 94, 295-301.
- 19. Williamson E, Driver S, Baxter K. Stockley’s herbal medicines interactions 1st ed. Londra: Pharmaceutical Press; 2009. p.1-11, 24-6, 167-70, 195-6; 198-203, 207-18, 219-25, 272-6, 349- 52, 360-80, 394-97.
- 20. Smith TW. Digitalis: Mechanisms of action and clinical use. N Engl J Med. 1988;318(6):358-65.
- 21. Akyol A. Dijital zehirlenmesinde hemşirenin sorumlulukları. EGEHFD. 1999;15(2-3):151-63.
- 22. Bhatia SJ. Digitalis toxicity turning over a new leaf? West J Med. 1986;145(1)74-82.
- 23. Kanji S, MacLean RD. Cardiac glycoside toxicity: More than 200 years and counting. Crit Care Clin. 2012;28(4):527-35.
- 24. Park MK. The use of digoxin in infants and children with specific emphasis on dosage. J Pediatr 1986;108(6):871-7.
- 25. Das BB, Moskowitz WB, Butler J. Current and future drug and device therapies for pediatric heart failure patients: potential lessons from adult trials. Children (Basel). 2021;8(5):322.
- 26. Meissner JE. Reducing the risk of toxicity. Nursing 1980;10(9):32-37.
- 27. Soyka LF. Clinical pharmacology of digoksin. Pediatr Clin North Am. 1972;19(1):241-56.
- 28. Haklin H, Radomsky M, Blieden L, Frand M, Millman P, Boichis H. Steady state serum digoxin concentration in relation to digitalis toxicity in neonates and infants. Pediatrics. 1978;61(2):184-88.
- 29. Tuncok Y, Hazan E, Oto O, Guven H, Catalyurek H, Kalkan S. Relationship between high serum digoxin levels and toxicity. Int J Clin Pharmacol Ther. 1997;35(9):366-68.
- 30. Çiftçi E, Aydın S. Toxicological evaluation of digital glycosides in congestive heart failure. FABAD J Pharm Sci. 2018;43(3):296-307. 31. Goldberger AL, Goldberger ZD, Shvilkin A. Goldberger’s clinical electrocardiography. 8th ed. Elsevier; 2018. p.211-216.
- 32. Işık K. Acil Kalp hastalıklarında teşhis ve tedavi. 1. Basım. İstanbul Matbaası; İstanbul. 1986. p.251-63.
- 33. Cooke DM. Shielding Your Patient. Nursing 1992;22(7):44-47.
- 34. Murpy TG. Digoxin toxicity ventricular dysrhytmias to watch for. AJN. 1993;93(12):37-41.
- 35. Esen A. Dijital tedavisi ve hemşirenin sorumlulukları. EGEHFD. 1993;9:3.
- 36. Fee WH. Activated charcoal safe and effective for digoxin toxicity. Am J Med. 2008;116(6):430.
- 37. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila). 2012;49(10):910-41.
- 38. Kervancıoğlu M, Özbek MN, Devecioğlu C, Sucaklı İ. Ondört günlük bir yenidoğanda digoksin intoksikasyonu: Olgu sunumu. Dicle Univ Tip Fakul Derg, 2006;33(1):45-47.
- 39. Park MK, Salamat M. Park’s pediatric cardiology for practitioners, 4th edt. St.Louis, Missouri, Mosby; 2002. p.403-406.
- 40. Cambonie G, Haack K, Guyon G. Digitalis intoxication during the neonatal period: role of dehydration. Arch Pediatr. 2000;7(6):633-36.
- 41. Hu YH, Tai CT, Tsai CF, Huang MW. Improvement of adequate digoxin dosage: an application of machine learning approach. J Healthc Eng. 2018;3948245.
- 42. Yao SH, Tsai HT, Lin WL, Chen YC, Chou C, Lin HW. Predicting the serum digoxin concentrations of infants in the neonatal intensive care unit through an artificial neural network. BMC Pediatrics, 2019;19(1):517.
Toplam 40 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Derlemeler |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Eylül 2023 |
| Gönderilme Tarihi | 4 Temmuz 2022 |
| Yayımlandığı Sayı | Yıl 2023 Cilt: 3 Sayı: 3 |
